Preusser, Matthias
Lim, Michael
Hafler, David A.
Reardon, David A.
Sampson, John H.
Article History
First Online: 11 August 2015
Competing interests
: M.P. has received honoraria, research support (unrestricted grants), and travel support (to scientific meetings) from Bristol-Myers Squibb, Böhringer-Ingelheim, GlaxoSmithKline, Mundipharma and Roche. M.L. has received research support from Agenus, Arbor Pharmaceuticals, Bristol-Myers Squibb, Celldex Therapeutics, and ImmunoCellular Therapeutics, and has served as a consultant for Bristol-Myers Squibb. D.A.H. has consulted for Allergan Pharmaceuticals, Bristol-Myers Squibb, EMD Serono, Genzyme Sanofi-Aventis, MedImmune, Mylan Pharmaceuticals, Novartis Pharmaceuticals, Questcor and Teva Neuroscience, and has received grant support from Bristol-Myers Squibb. D.A.R. has received financial compensation for participation in advisory boards for Amgen, Cavion, Genentech/Roche, Midatech Pharma, Momenta Pharmaceuticals, Novartis and Stemline Therapeutics, served as a member of speakers' bureaus for Genentech/Roche and Merck, and received research support from Celldex Therapeutics and Incyte. J.H.S. declares no competing interests.
Free to read: This content has been made available to all.